CSPC PHARMA (01093) announced that, effective November 4, 2025, Mr. Pan Weidong has resigned as an executive director and ceased to serve as the company's authorized representative under Rule 3.05 of the Hong Kong Stock Exchange Listing Rules due to personal commitments requiring more time. Dr. Li Chunlei, an executive director of the company, has been appointed as the new authorized representative.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.